白血病
急性白血病
医学
肿瘤科
内科学
癌症研究
作者
Eytan M. Stein,Guillermo Garcia‐Manero,David A. Rizzieri,Raoul Tibes,Jesús G. Berdeja,Michael R. Savona,Mojca Jongen-Lavrenic,Jessica K. Altman,Blythe Thomson,Stephen J. Blakemore,Scott R. Daigle,Nigel J. Waters,A. Benjamin Suttle,Alicia Clawson,Roy M. Pollock,Andrei V. Krivtsov,Scott A. Armstrong,Jorge DiMartino,Eric Hedrick,Bob Löwenberg
出处
期刊:Blood
[Elsevier BV]
日期:2018-05-03
卷期号:131 (24): 2661-2669
被引量:457
标识
DOI:10.1182/blood-2017-12-818948
摘要
Key Points Pinometostat demonstrates first evidence of DOT1L target inhibition and clinical responses in a subset of MLL-r advanced leukemia patients. The observed safety profile of pinometostat shows potential for exploration of combination therapies in leukemia.
科研通智能强力驱动
Strongly Powered by AbleSci AI